News Release #8 - Advanced DNA Regenerative Wound Care Product Lines
Updated: May 23
BCM Develops Advanced DNA Regenerative Wound Care Product Lines
BCM Industries has developed a number of new regenerative tissue technologies and products that assure a reduced level of patient rejection of human tissue. These advanced products are designed to deliver a higher level of surgical success, a reduction of common side effects, improved patient healing and recovery time, and a lower total lifetime medical and lost employment income costs.
There are many types of wounds, burns, scars or desired body changes that medical professionals can address by employing BCM product lines that include B Matrix™, the Cutus Novem Scaffold™ and/or the Tilage Scaffold™.
BCM specializes by providing wound healing for difficult and/or impossible to heal wounds. Typically the term “difficult to heal” means the wound is in a location on the body that encounters a lot of movement (a lot of skin stretching and torque)– or no movement (a more limited blood circulation location). The term “impossible to heal” means the open wound area is not able to generate skin in surfactant volume to cover the open wound or such an event will require a long period of time thus exposing the open wound to a high risk of infection.
Wound care in the USA is found as a part of the number of physician office visits for unintentional injuries: 39.5 million. It also is within the number of emergency department visits for unintentional injuries: 29.2 million. (2018).
Diabetic Foot Ulcer (DFU) is one of many specialized segment of the wound care service market. For those patients suffering from diabetes mellitus, during their lifetime, it is estimated that between 15% and 25% of these patients, during their lifetime will incur skin ulcers below their ankles. These DFU seriously affect the patient’s quality of life, can be limb-and life-threatening, and are responsible for a majority of hospital admissions among diabetics.
DFUs constitute a major public health burden in both the developed and developing countries . It terms of population impact there are nearly 26 million people with diabetes in the in the USA. Globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980.  That translates into more than 6 million DFU patients in the USA and over 105 million worldwide. 
BCM skin products are designed to assist healthcare professionals in addressing DFU issues of wound closure. The lifetime risk of a foot ulcer in patients with diabetes (Type 1 or 2) may be as high as 34 percent. [1-3] Diabetic foot ulcers are a major cause of morbidity , accounting for approximately two-thirds of all nontraumatic amputations performed in the United States. [5,6]
Infected or ischemic diabetic foot ulcers account for approximately 25 percent of all hospital stays for patients with diabetes.  These observations illustrate the importance of prompt and appropriate treatment of foot ulcers in patients with diabetes.
The BCM regenerative advanced wound care system will be a complete kit that includes the required materials for a successful tissue regeneration. The kits include all items, devices, instruction procedures and supplies for the complete patient’s autologous tissue regeneration and replacement.
To meet the unique needs of each individual patients, BCM will provide multiple size Cutus Novem Scaffold™ Kits. These Kits are based upon the size of the wound that requires treatment, from 0.01 sq. meters (10cm x 10cm) up to 1 square meter.
The regulatory approved delivery of these BCM wound care products to hospitals and health care facilities is scheduled to commence in late 2020. Interested hospital, treatment centers, surgeons and possible recipients of BCM delivered skin burn injury regenerative products should contact BCM Industries or the Right To Heal Foundation at their websites.
Sources: https://www.uptodate.com/contents/management-of-diabetic-foot-ulcers  Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31:1679.  National Diabetes Data Group. Diabetes in America, 2nd Edition, National Institutes of Health, Washington, D.C p.409.  American Diabetes Association. Clinical Practice Recommendations: foot care in patients with diabetes mellitus. Diabetes Care 1996; 19:S23.  Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med 2017; 376:2367.  Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22:382.  Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27:1591.  American Diabetes Association: Statistics about diabetes: diabetes from the national diabetes statistics report, 2014 (released 06/10/14). http://www.diabetes.org/diabetes-basics/statistics/ (Accessed on September 02, 2015).  source: Global Epidemiology of Diabetic Foot Ulceration: A Systematic Review and Meta-Analysis https://www.researchgate.net/publication/307577314_Global_Epidemiology_of_Diabetic_Foot_Ulceration_A_Systematic_Review_and_Meta-Analysis  WHO https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=7E1807FAEF9C41E8EF5A7A8F4594F5DA?sequence=1